NovaBridge Biosciences Financials

NBP

Source SEC Filings (10-K/10-Q) Updated Jun 30, 2025 Currency USD FYE December

This page shows NovaBridge Biosciences (NBP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

2/9

NovaBridge Biosciences passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

2.37x

For every $1 of reported earnings, NovaBridge Biosciences generates $2.37 in operating cash flow (-$52.7M OCF vs -$22.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Revenue

N/A

EBITDA

-$51.1M

YoY+28.5%

NovaBridge Biosciences's EBITDA was -$51.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 28.5% from the prior year.

Free Cash Flow

-$52.7M

YoY+71.3%

NovaBridge Biosciences generated -$52.7M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 71.3% from the prior year.

Net Income

-$22.2M

YoY+89.3%

NovaBridge Biosciences reported -$22.2M in net income in fiscal year 2024. This represents an increase of 89.3% from the prior year.

EPS (Diluted)

$-0.12

YoY+89.0%

NovaBridge Biosciences earned $-0.12 per diluted share (EPS) in fiscal year 2024. This represents an increase of 89.0% from the prior year.

Cash & Debt

$68.3M

YoY-76.6%

5Y CAGR-16.0%

NovaBridge Biosciences held $68.3M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

187M

YoY+1.0%

5Y CAGR+7.1%

NovaBridge Biosciences had 187M shares outstanding in fiscal year 2024. This represents an increase of 1.0% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$21.8M

YoY+1.5%

5Y CAGR-29.0%

NovaBridge Biosciences invested $21.8M in research and development in fiscal year 2024. This represents an increase of 1.5% from the prior year.

Share Buybacks

$335K

YoY-96.1%

NovaBridge Biosciences spent $335K on share buybacks in fiscal year 2024, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 96.1% from the prior year.

Capital Expenditures

$48K

YoY-70.7%

5Y CAGR-51.3%

NovaBridge Biosciences invested $48K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 70.7% from the prior year.

NBP Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	$632K	N/A	$13.8M-94.2%	$236.4M+5386.7%	$4.3M
Cost of Revenue	N/A	N/A	$3.9M-45.8%	$7.3M	N/A	N/A
Gross Profit	N/A	N/A	-$5.5M-184.3%	$6.5M	N/A	N/A
R&D Expenses	$21.8M+1.5%	$21.4M-4.9%	$22.5M-88.2%	$190.3M+26.1%	$150.9M+25.0%	$120.7M
SG&A Expenses	$29.7M+5.3%	$28.2M-2.8%	$29.0M-79.5%	$141.2M+129.0%	$61.7M-34.4%	$94.0M
Operating Income	-$51.4M+28.6%	-$72.0M-35.7%	-$53.1M	N/A	N/A	N/A
Interest Expense	N/A	$102K+10100.0%	$1K	$0-100.0%	$147K-65.8%	$430K
Income Tax	$0	$0-100.0%	$103K+120.8%	-$495K-126.4%	$1.9M	N/A
Net Income	-$22.2M+89.3%	-$207.7M+44.0%	-$371.1M-1.4%	-$365.9M-607.0%	$72.2M+134.6%	-$208.6M
EPS (Diluted)	$-0.12+89.0%	$-1.09+44.4%	$-1.96+6.2%	$-2.09-554.3%	$0.46+101.6%	$-28.90

Metric	Q2'25	Q2'24	Q4'23	Q4'22	Q2'22	Q4'21	Q4'20	Q3'20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

NBP Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$212.7M-42.4%	$368.9M-37.5%	$590.6M-32.8%	$878.9M-9.5%	$970.7M+288.9%	$249.6M
Current Assets	$176.7M-46.4%	$329.9M-37.3%	$525.8M-29.9%	$750.4M-8.4%	$819.0M+318.8%	$195.5M
Cash & Equivalents	$68.3M-76.6%	$291.5M-15.0%	$342.9M-38.0%	$552.9M-24.2%	$729.3M+346.4%	$163.4M
Inventory	N/A	N/A	$0-100.0%	$4.3M	N/A	N/A
Accounts Receivable	N/A	N/A	$0-100.0%	$5.2M-74.0%	$20.0M	N/A
Goodwill	N/A	N/A	$23.6M-7.6%	$25.5M+2.4%	$24.9M+6.7%	$23.4M
Total Liabilities	$11.5M-90.9%	$126.3M-25.1%	$168.7M+3.2%	$163.5M+50.9%	$108.3M-80.0%	$541.9M
Current Liabilities	$8.5M-85.5%	$58.1M-47.1%	$109.9M+12.3%	$97.9M+10.9%	$88.3M+4.5%	$84.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$201.2M-17.1%	$242.6M-41.9%	$417.8M-41.6%	$715.1M-17.1%	$862.4M+395.1%	-$292.3M
Retained Earnings	-$1.3B-1.8%	-$1.3B-27.0%	-$994.9M-45.6%	-$683.4M-120.4%	-$310.1M+13.4%	-$358.3M

Metric	Q2'25	Q2'24	Q4'23	Q4'22	Q2'22	Q4'21	Q4'20	Q3'20
Total Assets	$206.7M-2.8%	$212.7M-42.4%	$368.9M-37.5%	$590.6M-20.7%	$745.2M-15.2%	$878.9M-9.5%	$970.7M+53.3%	$633.0M
Current Assets	$167.6M-5.1%	$176.7M-46.4%	$329.9M-37.3%	$525.8M-18.4%	$644.2M-14.2%	$750.4M-8.4%	$819.0M+73.3%	$472.5M
Cash & Equivalents	$165.4M+142.3%	$68.3M-76.6%	$291.5M-15.0%	$342.9M-38.1%	$554.0M+0.2%	$552.9M-24.2%	$729.3M+67.3%	$436.0M
Inventory	N/A	N/A	N/A	$0	N/A	$4.3M	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	$0-100.0%	$76K-98.5%	$5.2M-74.0%	$20.0M	N/A
Goodwill	N/A	$23.4M	N/A	$23.6M-2.9%	$24.3M-4.9%	$25.5M+2.4%	$24.9M+4.1%	$23.9M
Total Liabilities	$10.0M-13.4%	$11.5M-90.9%	$126.3M-25.1%	$168.7M+15.9%	$145.6M-10.9%	$163.5M+50.9%	$108.3M+32.1%	$82.0M
Current Liabilities	$7.3M-13.1%	$8.5M-85.5%	$58.1M-47.1%	$109.9M+24.8%	$88.1M-10.0%	$97.9M+10.9%	$88.3M+71.6%	$51.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$196.7M-2.2%	$201.2M-17.1%	$242.6M-41.9%	$417.8M-30.3%	$599.6M-16.2%	$715.1M-17.1%	$862.4M+56.5%	$551.1M
Retained Earnings	-$1.3B-0.7%	-$1.3B-1.8%	-$1.3B-27.0%	-$994.9M-23.4%	-$806.5M-18.0%	-$683.4M-120.4%	-$310.1M+31.3%	-$451.4M

NBP Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$52.7M+71.3%	-$183.8M-15.0%	-$159.9M-4.7%	-$152.7M-329.8%	$66.4M+153.3%	-$124.7M
Capital Expenditures	$48K-70.7%	$164K-92.2%	$2.1M-55.5%	$4.7M+282.8%	$1.2M-30.2%	$1.8M
Free Cash Flow	-$52.7M+71.3%	-$184.0M-13.6%	-$162.0M-2.9%	-$157.4M-341.3%	$65.2M+151.6%	-$126.4M
Investing Cash Flow	N/A	$14.4M-78.3%	$66.5M+158.2%	-$114.1M-268.8%	-$30.9M-201.4%	$30.5M
Financing Cash Flow	N/A	$1.1M-82.6%	$6.1M-93.4%	$93.2M-82.3%	$527.3M+2303.7%	$21.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$335K-96.1%	$8.6M+187.6%	$3.0M	$0-100.0%	$5.3M	N/A

Metric	Q2'25	Q2'24	Q4'23	Q4'22	Q2'22	Q4'21	Q4'20	Q3'20
Operating Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	$152.3M	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	$526K	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	$151.7M	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	$6.8M	N/A
Financing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	$145.0M	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	$208K	N/A

NBP Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	47.3%	N/A	N/A
Operating Margin	N/A	-11395.1%	N/A	N/A	N/A	N/A
Net Margin	N/A	-32868.5%	N/A	-2648.7%-2679.3pp	30.5%+4870.6pp	-4840.1%
Return on Equity	N/A	N/A	N/A	N/A	8.4%	N/A
Return on Assets	-10.4%+45.9pp	-56.3%+6.5pp	-62.8%-21.2pp	-41.6%-49.1pp	7.4%+91.0pp	-83.6%
Current Ratio	20.90+15.2	5.67+0.9	4.78-2.9	7.66-1.6	9.28+7.0	2.31
Debt-to-Equity	0.06-0.5	0.52+0.1	0.40+0.2	0.23+0.1	0.13+2.0	-1.85
FCF Margin	N/A	-29107.9%	N/A	-1139.5%-1167.1pp	27.6%+2961.8pp	-2934.2%

Metric	Q2'25	Q2'24	Q4'23	Q4'22	Q2'22	Q4'21	Q4'20	Q3'20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Current Ratio	22.82+1.9	20.90+15.2	5.67+0.9	4.78-2.5	7.31-0.3	7.66-1.6	9.28+0.1	9.18
Debt-to-Equity	0.050.0	0.06-0.5	0.52+0.1	0.40+0.2	0.24+0.0	0.23+0.1	0.13-0.0	0.15
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Frequently Asked Questions

Is NovaBridge Biosciences profitable?

No, NovaBridge Biosciences (NBP) reported a net income of -$22.2M in fiscal year 2024.

What is NovaBridge Biosciences's earnings per share (EPS)?

NovaBridge Biosciences (NBP) reported diluted earnings per share of $-0.12 for fiscal year 2024. This represents a 89.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is NovaBridge Biosciences's EBITDA?

NovaBridge Biosciences (NBP) had EBITDA of -$51.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is NovaBridge Biosciences's free cash flow?

NovaBridge Biosciences (NBP) generated -$52.7M in free cash flow during fiscal year 2024. This represents a 71.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is NovaBridge Biosciences's operating cash flow?

NovaBridge Biosciences (NBP) generated -$52.7M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are NovaBridge Biosciences's total assets?

NovaBridge Biosciences (NBP) had $212.7M in total assets as of fiscal year 2024, including both current and long-term assets.

What are NovaBridge Biosciences's capital expenditures?

NovaBridge Biosciences (NBP) invested $48K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does NovaBridge Biosciences spend on research and development?

NovaBridge Biosciences (NBP) invested $21.8M in research and development during fiscal year 2024.

Does NovaBridge Biosciences buy back shares?

Yes, NovaBridge Biosciences (NBP) spent $335K on share buybacks during fiscal year 2024, returning capital to shareholders by reducing shares outstanding.

How many shares does NovaBridge Biosciences have outstanding?

NovaBridge Biosciences (NBP) had 187M shares outstanding as of fiscal year 2024.

What is NovaBridge Biosciences's current ratio?

NovaBridge Biosciences (NBP) had a current ratio of 20.90 as of fiscal year 2024, which is generally considered healthy.

What is NovaBridge Biosciences's debt-to-equity ratio?

NovaBridge Biosciences (NBP) had a debt-to-equity ratio of 0.06 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is NovaBridge Biosciences's return on assets (ROA)?

NovaBridge Biosciences (NBP) had a return on assets of -10.4% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is NovaBridge Biosciences's cash runway?

Based on fiscal year 2024 data, NovaBridge Biosciences (NBP) had $68.3M in cash against an annual operating cash burn of $52.7M. This gives an estimated cash runway of approximately 16 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is NovaBridge Biosciences's Piotroski F-Score?

NovaBridge Biosciences (NBP) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are NovaBridge Biosciences's earnings high quality?

NovaBridge Biosciences (NBP) has an earnings quality ratio of 2.37x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.